annb0t
Top 20
The latest analyst coverage could presage a bad day for Mayne Pharma Group Limited (ASX:MYX), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.
Following the latest downgrade, the four analysts covering Mayne Pharma Group provided consensus estimates of AU$345m revenue in 20...
>>> Read more: Mayne Pharma Group Limited (ASX:MYX) Analysts Just Trimmed Their Revenue Forecasts By 19%
Following the latest downgrade, the four analysts covering Mayne Pharma Group provided consensus estimates of AU$345m revenue in 20...
>>> Read more: Mayne Pharma Group Limited (ASX:MYX) Analysts Just Trimmed Their Revenue Forecasts By 19%
